Please login to the form below

Not currently logged in
Email:
Password:

Abraxane

This page shows the latest Abraxane news and features for those working in and with pharma, biotech and healthcare.

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq has already been approved in combination with Abraxane (nab-paclitaxel), after demonstrating a statistically significant PFS benefit and clinically meaningful improvements in OS for people with metastatic TNBC whose tumours

Latest news

More from news
Approximately 14 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    cells. A good example of this is the combined use of  Abraxane  and  gemcitabine  in the treatment of  metastatic adenocarcinoma  of the pancreas – Abraxane helps to inhibit cancer cell growth, and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....